Associations of Combinations of Single-nucleotide Polymorphisms in Women With Premature Ovarian Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

238 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2023-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research objective.

\- To study the associations between combinations of single nucleotide polymorphisms and behavioural risk factors with non-communicable diseases and adverse outcomes in women with premature ovarian failure.

Research objectives:

* To study the associations between combinations of single-nucleotide polymorphisms and behavioural risk factors with heart rate disorders and adverse outcomes in women with premature ovarian failure
* Examine the associations between combinations of single nucleotide polymorphisms and behavioural risk factors with stable STIs in women with premature ovarian failure.
* Examine the associations between combinations of single nucleotide polymorphisms and behavioural risk factors with thrombomolia in women with premature ovarian failure
* Study the associations between combinations of single nucleotide polymorphisms and behavioural risk factors and adverse cardiovascular outcomes in women with premature ovarian failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Contraceptive and Cardiovascular Risk in PCOS

NCT00593294

Polycystic Ovary Syndrome

COMPLETED PHASE4

Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome

NCT01859663

Polycystic Ovary Syndrome Dietary Habits Physical Activity

COMPLETED

Optimising Preconceptual Health in Subfertile PCOS Patients Using a Lifestyle Modification Program

NCT05084274

Infertility, Female Polycystic Ovarian Syndrome Lifestyle

TERMINATED NA

Lifestyle Factors Study

NCT00989183

Reproductive Age Oophorectomy for Benign Indications

COMPLETED

Health Risks and Barriers to Management Across the PCOS Lifespan

NCT05769426

Polycystic Ovary Syndrome Menopause

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods of research:

* Questionnaire .
* Clinical examination
* Blood levels of sex hormones
* Blood lipid spectrum
* Coagulogram
* Glycemic profile
* EchoCG
* SMAD
* ECG
* Daily ECG monitoring
* Questionnaire EQ-5D
* Single-nucleotide polymorphisms of genes of the reninangyotensin-aldosterone system group (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), pro-inflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) polymorphisms.

Subject of study.

Women under 45 with Premature Ovarian Failure (PED). It is planned to include 615 people in the study. The study will have both prospective and retrospective parts. Patients will be divided into 4 groups:

* Women with OED without cardiovascular disease
* Women with OAI who have cardiovascular disease
* Control group No 1 Women with normal ovarian function without cardiovascular disease.
* Control group 2 Women with normal ovarian function without cardiovascular disease.

The groups will be comparable in number. All data obtained will be calculated for each group separately. A comparative analysis will then be made for all four groups.

Traditional risk factors, existing non-communicable diseases and the quality of life of patients will be identified using standard research methods.

The selected polymorphism groups are associated with various pathological processes leading to unfavourable cardiovascular outcomes. Their role has not been assessed in patients with premature ovarian failure.

The power of the study was calculated based on the expected number of adverse outcomes.

The division of patients into groups is related to the need to compare and evaluate unfavourable outcomes and non-communicable diseases in patients in order to create a risk scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Ovarian Insufficiency Cardiovascular Diseases Menopause, Premature Coronary Disease Pulmonary Embolism Arrhythmias, Cardiac Polymorphism, Single Nucleotide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Women diagnosed with premature ovarian failure were selected from different medical institutions in Ryazan and the Ryazan region, all information was communicated to them in a clear and understandable way and they also signed an informed voluntary consent. Premature ovarian failure - defined as the occurrence of secondary amenorrhoea ≥4 months at the age of under 45 years together with FSH levels above 40 IU/L.

Inclusion criteria were: female gender, age at menopause \< 45 years, onset of secondary amenorrhoea ≥ 4 months, FSH levels higher than 40 IU/l, or a previous diagnosis of premature ovarian failure.

The control group was formed based on comparability criteria of gender, age and BMI to minimise the influence of phenotype on the results. The control group consisted of women without signs of PEN, so we aimed to compare the health status of these two different groups of women.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study of single-nucleotide polymorphisms in women diagnosed with premature ovarian failure

Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), proinflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in the study group of women diagnosed with premature ovarian failure.

Group Type ACTIVE_COMPARATOR

Taking a person's venous blood

Intervention Type BEHAVIORAL

Collection of 5 ml of the patient's venous blood, carried out according to standard rules.

Study of single-nucleotide polymorphisms in a control group of healthy women

Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), pro-inflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in a control group of healthy women .

Group Type ACTIVE_COMPARATOR